Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Orthocell Ltd ( (AU:OCC) ) has issued an announcement.
Orthocell Limited held its Annual General Meeting where the Chair and Managing Director addressed stakeholders. The company continues to expand its market presence with recent product approvals and initial sales in the US, enhancing its position in the regenerative medicine industry. This growth is supported by a network of specialist distributors and ongoing development of its tendon cell therapy in the US.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Its product portfolio includes collagen medical devices for dental and orthopedic applications, as well as nerve and tendon repair products. The company operates globally with products approved in multiple countries, including the US, Australia, and Europe.
Average Trading Volume: 755,786
Technical Sentiment Signal: Buy
Current Market Cap: A$314.2M
For a thorough assessment of OCC stock, go to TipRanks’ Stock Analysis page.